IMTX (Immatics NV) Debt-to-Asset : 0.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMTX Immatics NV IMTX
60 GF Score
Price $9.56
GF Value $4.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Immatics NV Debt-to-Asset?

Immatics NV IMTX +1.06% 60 Debt-to-Asset is 0.03 as of Jun. 2026. GuruFocus rates IMTX with a GF Score™ of 60/100 and a GF Value™ of $4.29 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Immatics NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $3.07 Mil. Immatics NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $13.76 Mil. Immatics NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $559.60 Mil. Immatics NV's debt to asset for the quarter that ended in Jun. 2026 was 0.03.

Immatics NV  (NAS:IMTX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Immatics NV Debt-to-Asset Related Terms

Immatics NV Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Immatics NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immatics NV Debt-to-Asset Chart

Immatics NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.06 0.04 0.03 0.02 0.03

Immatics NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.03

IMTX vs AKTS, REPL, CGEM: Debt-to-Asset Comparison

For the Biotechnology subindustry, Immatics NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immatics NV Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immatics NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Immatics NV's Debt-to-Asset falls into.


IMTX
60GF Score
Immatics NV IMTX
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immatics NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Immatics NV's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(3.228 + 15.08) / 658.474
=0.03

Immatics NV's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(3.071 + 13.756) / 559.603
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.03 mean?
Immatics NV (IMTX) has a Debt-to-Asset of 0.03 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Immatics NV and its competitors.
Is Immatics NV's Debt-to-Asset too high?
Immatics NV's current Debt-to-Asset is 0.03. Overall, Immatics NV has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's Debt-to-Asset compare to AKTS and REPL?
Immatics NV's Debt-to-Asset of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Immatics NV and its competitors. Immatics NV's current Debt-to-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.29, compared to a current price of $9.56 — trading 122.8% above its estimated fair value. The current Debt-to-Asset is 0.03. Immatics NV's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Immatics NV (IMTX), the current Debt-to-Asset is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immatics NV (IMTX) Overvalued in 2026?

Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued. The current stock price of $9.56 is trading 122.8% above its estimated GF Value™ of $4.29. GuruFocus considers Immatics NV to be Significantly Overvalued.

Key valuation signals for IMTX:

  • Debt-to-Asset: 0.03
  • GF Value™: $4.29 vs. price of $9.56 (122.8% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immatics NV Business Description

Other Exchanges 4A3:Germany
Address Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score

Get the complete analysis for IMTX

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.56
Price
$4.29
GF Value